Citations

Clear

1417 citation(s) found for "Simon, FM".

S15:01 Safety and efficacy of CD19 NEX-T® (BMS-986353)—a CD19-directed chimeric antigen receptor (CAR) T cell therapy—for severe refractory systemic lupus erythematosus (SLE): breakfree-1 trial update
Simon, David Nils , Wiesendanger, Margrit, Langhe, Ellen De, Askanase, A., Schett, Georg, Saxena, Amit, Kramer, Neil E., Mease, P, Schmalzing, Marc , Melton, Alexis, Law, Brandon M., Handy, Whitney, McTume, Griff, Ide, Takafumi , Harnois, Melissa J. , Thorpe, Jerill , Koegel, Ashley Kern, Littlejohn, Emily , Simon, David , Langhe, Ellen De , Majithia, Vikas , Schett, Georg , Saxena, Amit , Kramer, Neil, Desai, Alisha, McTume, G., Ide, Takafumi

Mayo Clinic

Oral Presentations | March 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: A24-A25

10.1136/lupus-2026-el.21 Get It

Abstract RF7-07: Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival
DeMichele, A. M., Dueck, A., Gnant, M., Martín, M., Wolff, A., Rubovsky, Gabor, Henao, F., Hahn, O. M., Chan, A., Brusky, A., Morris, PG, Burstein, H., Huber, G., Anderson, D., Garcia-Estevez, L., Pfeiler, G., Rugo, H., Zdenkowski, N., Wolmark, N., Sabanathan, D., Miller, K., Cameron, D., Winer, E., Brunner, C., Gauthier, E., O’Brien, P., Fesl, Christian , Mayer, E. L., DeMichele, Angela , Gnant, Michael , Hlauschek, Dominik , Rubovsky, Gabor , Pfeiler, Georg , Zdenkowski, Nicholas , Gampenrieder, Simon Peter , Sabanathan, Danusha, Miller, K., Gauthier, ER, O’Brien, P.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: RF7-07-RF7-07

10.1158/1557-3265.sabcs25-rf7-07 Get It

Abstract PURPOSE: CDK4/6 inhibitors (CDK4/6i), used in combination with endocrine therapy (ET), are standard of care for advanced and higher risk early stage hormone receptor-positive (HR+), HER2 negative (HER2-) breast cancer. PALLAS investigated the addition of 2 years (y) of palbociclib to adjuvant ET (ET/P) compared to ET alone in patients (pts) with stage II-III HR+/HER2- breast cancer. We now present overall survival (OS) with 7-y outcomes and impact of post-recurrence therapy. PATIENTS AND METHODS: This global phase III trial randomized pts to ET for at least 5 y with or without 2 y of P. Primary endpoint was iDFS; distant recurrence-free survival (DRFS) and OS were preplanned endpoints. Kaplan Meier estimates and hazard ratios (HR) from Cox and Fine & Gray models were performed. Post-recurrence OS was analyzed as time from first distant recurrence (DR) until death. The post-recurrence OS model adjusted for both clin/path factors (including DR-free y, DR site) and time-dependent post-DR therapy (chemo, CDK4/6i). Results: 5,796 pts enrolled at 406 centers in 21 countries worldwide over 3 y. In the intent-to-treat (ITT) population, with a median follow-up of 82.7 months (mo), 7-y outcomes for iDFS, DRFS and OS are shown in the table. DR occurred in 781 pts (377 ET/P, 404 ET alone) with balanced pt/disease characteristics between arms. ET/P had more visceral (46% vs. 36%) and fewer non-visceral (61% vs. 68%) DR compared to ET alone (p=0.03). Unadjusted post-recurrence OS was significantly worse for ET/P vs. ET (median 22.6 vs. 27.9 mo, HR 1.21 (95% CI 1.01-1.46, p=0.04). However, receipt of any post-recurrence CDK4/6i was significantly higher on ET vs. ET/P arms (41% vs. 66%) and time to post-progression CDK4/6i initiation was significantly shorter for those in the ET vs. ET/P arms (HR 0.50, 95% CI 0.41-0.61, p<0.001) adjusting for region, bone/visceral DR type, DR-free time and age. Conversely, time to post-progression chemotherapy initiation was significantly longer for ET alone vs. ET/P arms (HR 1.31, 95% CI 1.07-1.61, p=0.01). However, after adjustment for clinical factors and post-DR treatment, the OS difference was no longer seen (HR 1.05, 95% CI 0.85-1.28, p=0.65). 3-mo landmark analysis showed similar effect on OS after adjusting for CDK4/6i initiation within 3 mo from DR (unadjusted HR 1.24, p=0.03 vs. adjusted HR 1.15, p=0.22). CONCLUSION: The PALLAS trial revealed significant differences in treatment post-DR that impact OS. Reduced/delayed use of metastatic CDK4/6i after adjuvant P was associated with significantly poorer OS, suggesting that patients who relapse after adjuvant CDK4/6i may still benefit from metastatic CDK4/6i. This has implications for optimal treatment in those who relapse after adjuvant CDK4/6i and warrants further study to determine if this is therapy-specific or an overarching biological effect. SUPPORT: AFT, ABCSG, NRG, PrECOG; Pfizer Citation Format: A. DeMichele, A. Dueck, M. Gnant, D. Hlauschek, M. Martin, A. Wolff, G. Rubovsky, F. Henao, O. Hahn, A. Chan, A. Brusky, P. Morris, H. Burstein, G. Huber, D. Anderson, L. Garcia-Estevez, G. Pfeiler, H. Rugo, N. Zdenkowski, S. Gampenrieder, N. Wolmark, D. Sabanathan, K. Miller, D. Cameron, E. Winer, C. Brunner, E. Gauthier, P. O’Brien, C. Fesl, E. Mayer. Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr RF7-07.
A precise atlas of the human subcortex
Friedrich, Helen, Sahin, Ilkem Aysu , Alho, Eduardo Joaquim Lopes , Holanda, Vanessa Milanese, Brammerloh, Malte , Matthies, Cordula , Volkmann, Jens, Meyer, Garance M. , Kirilina, E. ; https://orcid.org/0000-0003-1304-4363, Pijar, Julianna , Garimella, Arun , Fox, Michael D, Friedrich, Maximilian, Edlow, Brian L., Neudorfer, Clemens, Horn, Andreas, Li, Ningfei , Edlow, Brian L , Horn, Andreas , Rajamani, Nanditha , Oxenford, Simón , Mustin, Maike, Zvarova, Patricia , Krüger, Lara, Demann, Richard, Goede, Lukas L. , Kirilina, Evgeniya P. , Volkmann, Jens , Horisawa, Shiro , Howard, Calvin, Fox, Michael , Friedrich, Maximilian, Bochtler, Anja, Edlow, Brian L. , Neudorfer, Clemens , Horn, Andreas

Mayo Clinic

No container title available | February 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.13.705755 | PMID 41726876 Get It

Abstract Clinical interventions and neuroimaging in the subcortex require anatomical definitions that exceed the resolution and anatomical detail of currently available deformable brain atlases. Here, we introduce a high-resolution human brain atlas comprising 95 manually segmented grey and white matter structures as well as 82 white matter tracts compiled from a multitude of resources including ex-vivo MRI, histology, fibre dissections, and neuroanatomy textbooks. The atlas is defined at an isotropic resolution of 100 μm and can be precisely deformed to individual subject brain anatomy. By providing precise definitions of both grey and white matter structures within and around the basal ganglia, thalamus, subthalamus, midbrain and cerebellum, the atlas provides a foundational resource for stereotactic surgery and subcortical brain imaging research, as well as for development of next-generation neuromodulation strategies.
Transport vehicle–mediated TREM2 PET maps myeloid cells in the glioblastoma microenvironment
Brendel, M., Feng, Ruoqing, Mueller, Katharina, Kössinger, Anna Laura, Teske, Nina C. , Greve, Thomas, Kirchleitner, Sabrina Viktoria, Nikolaishvili, Elene, Lorenz, Julia , Hoermann, Leonie , Kunze, Lea H. , Schaefer, Rebecca , Liu, Lu , Haertel, Marlies, Dhoqina, Dario , Gnörich, Johannes, Turhan, Sena Gül, Ertürk, Ali, Thevis, Justus Flinn, Park, Ha Eun, Wind, Karin , Lindheimer, Felix, Zenatti, Valerio , Prestel, Matthias , Lichtenthaler, Stefan, Werner, Rudolf, Riemenschneider, Markus, Kalasauskas, Darius , Schmutzer-Sondergeld, Michael, Stoecklein, Veit M. , Ringel, Florian , Meyer, Ana-Claire, Lewcock, Joseph W. , Monroe, Kathryn M. , Schlepckow, Kai , Haass, Christian, Herms, Jochen , Albert, Nathalie L. , Brendel, Matthias , Bartos, Laura M. , Mueller, K , Koessinger, Anna L. , Kirchleitner, Sabrina Viktoria , Blobner, Jens , Gnörich, Johannes , Müller, Stephan A. , Kolabas, Zeynep Ilgin , Ulukaya, Selin , Ertürk, Ali , Lindheimer, Felix , Bhat, Krishna , Tahirović, Sabina , Lichtenthaler, Stefan F. , Schmutzer-Sondergeld, Michael , Meyer, Ana-Claire, Haass, Christian , Baumgarten, Louisa von , Harter, Patrick N. , Simons, Mikael , Lindner, Simon

Mayo Clinic

No container title available | February 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8627080/v1 Get It

Abstract Glioblastomas exhibit low immunogenicity and a highly immunosuppressive tumor microenvironment (TME) mediated by both tumor cells and tumor associated microglia/macrophages (TAMs). However, biomarkers that allow for specific detection, monitoring and therapy response assessment of the TAM phenotype in glioblastoma are still lacking. To address this gap, we characterized the dynamics of TAM clusters in the TME of experimental SB28 glioblastoma using single-cell RNA sequencing, immunofluorescence, and molecular imaging and identified Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) as a dynamic TAM-specific target. Consequently, we investigated a novel 64 Cu-labeled TREM2 radiotracer with a blood-brain barrier transport vehicle for translational mapping of TAMs in the TME of glioblastoma. We found strong and highly myeloid cell-specific PET signals that followed the trajectory of TREM2 gene expression from early- towards late-stage tumors. Transient myeloid cell depletion via CSF1R inhibition showed a reduction of TREM2 PET signals compared to placebo and prolonged survival in SB28 glioblastoma mice, while TREM2 stimulation led to increased TREM2 PET signals. Translation into a pilot cohort of patients with glioblastoma revealed strong TREM2 PET signals predominantly at lesion edges and high heterogeneity across individuals, matching with immunohistochemistry. In summary, TREM2 PET imaging has strong potential as an immune cell-specific biomarker for personalized assessment of the TAM phenotype in the TME of patients with glioblastoma.
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis
Ammirati, Enrico, Palazzini, Matteo , Lehtonen, Jukka , Potena, Luciano , Mäyränpää, Mikko I. , Rågback, Johanna, Uribarri, Aitor , Thiele, H, Vidal‐Burdeus, María , Freund, Anne, Gustafsson, F., Tschöpe, C., Elsanhoury, Ahmed , Ihle, Joshua , Rudi, Wolf‐Stephan , Grabmaier, Ulrich , Merlo, Marco, Weislova, Ivana, Jellinghaus, Stefanie, Linke, A, Baldovini, Chiara , Adorisio, R, Kuchyňka, Petr, Palecek, T, Krejčí, Jan, Poloczková, Hana , Caterino, Anna Laura, Lovell, Jana , Macomb, Elaine P., Shih, Jeffrey, Hong, Kimberly N. , Ruschitzka, Frank, Cavallini, Claudio, Riccini, Clara, Kamal, Mohamed, Groh, Matthieu, Garascia, Andrea , Lala, Anuradha, Shimokawa, Hiroaki, Sionis, A, Schmidt, Matthieu, Grosu, Aurelia, Bollano, Entela , Turco, Annalisa , Crespo-Leiro, M., Couto-Mallón, David, Cannata, Antonio, Narducci, M L, Cicchitti, Vincenzo , Ianni, Umberto , L, De Luca, Frea, Simone, Schroeder, J. W., Arias, Aníbal , Emdin, Michele, Corda, Marco , Pasqualucci, Daniele , Greulich, Simon , Gawaz, M, Manuylova, Tatiana, Martinez-Selles, M, Pérez, Francisco José Hernández, Centellas, Alba Martín , Trankle, Cory R. , Halushka, Marc K., Abbate, Antonio, Basso, Cristina, Sinagra, Gianfranco, Veronese, Giacomo , Camici, PG, Adler, Eric D., Cooper, Leslie T., Gustafsson, Finn , Tschöpe, Carsten , Thiele, Hölger , Ammirati, Enrico , Potena, Luciano , Ammirati, Enrico , Foà, Alberto , Uribarri, Aitor , Thiele, Holger , Vidal-Burdeus, María , Freund, Anne , Gustafsson, Finn , Tschöpe, Carsten , Elsanhoury, Ahmed , Ihle, Joshua , Grabmaier, Ulrich , Merlo, Marco , Melenovský, Vojtěch , Weislova, Ivana , Linke, Axel , Baldovini, Chiara , Kuchynka, Petr , Krejčí, Jan , Gilotra, Nisha A , Hong, Kimberly , Rossi, Valentina A , Ruschitzka, Frank T. , Kamal, Mohamed , Huang, Florent , Groh, Matthieu , Gentile, Piero , Garascia, Andrea , Shimokawa, Hiroaki , Vandenbriele, Christophe , Sionis, Alessandro , Schmidt, Matthieu , Bollano, Entela , Crespo-Leiro, Maria Generosa , Cannatà, Antonio , Bromage, Daniel I , Narducci, Maria Lucia , Cicchitti, Vincenzo , Ianni, Umberto , De Luca, Leonardo , Mistrulli, Raffaella , Frea, Simone , Raineri, Claudia , Schroeder, Jan W , Arias, Anibal Martin , Emdin, Michele , Greulich, Simon , Gawaz, Meinrad , Martínez-Sellés, Manuel , Hernández Pérez, Francisco José , Dominguez, Fernando , D'Alessandris, Nicoletta , Trankle, Cory , Halushka, Marc K , Moroni, Francesco , Abbate, Antonio , Basso, Cristina , Sinagra, Gianfranco , Veronese, Giacomo , Camici, Paolo G , Adler, Eric D , Bernasconi, Davide P , Klingel, Karin , Cooper, Leslie T , Foà, Alberto , Vidal-Burdeus, María , Merlo, M, Melenovský, Vojtěch , Adorisio, Rachele , Paleček, Tomáš , Krejčí, Jan , Cavallini, Claudio , Riccini, Clara, Gentile, Piero , Lala, Anuradha , Shimokawa, Hiroaki , Vandenbriele, Christophe , Couto‐Mallón, David , Luca, Leonardo De , Frea, Simone , Corda, Marco , Domínguez, Fernándo , Gaillet, Antoine , Halushka, Marc K. , Abbate, Antonio , Basso, Cristina , Cooper, Leslie T.

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 9 | Pages: 634-652

10.1161/circulationaha.125.074797 | PMID 41645905 Get It

BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34–59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%–48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis–associated form (13.1%) at 3 years ( P =0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06447935.
Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve
Thériault, Sébastien , Holdcraft, Jacob A., Sharipova, Dinara , Dębiec, Radosław , Peloso, Gina M., Al‐Kassou, Baravan , Swan, Elena Ashikhmina , Ballotta, Andrea, Björck, Hanna M. , Braund, Peter S. , Corriveau, François, Dagenais, François, Francke, Michael, Gorbatov, Svetlana, Guo, Dongchuan, Habchi, Karam M, Scouarnec, Solena Le , Lichtner, Peter , Nguyen, Thy B., Norris, R., Pibarot, P, Simonet, Floriane, Tm, Sundt, Tessler, Idit , Willer, Cristen J., Wittmann, Susanne, Yang, Bo, Berezovets, Igor, Doppler, S. , Dreßen, Martina, Knoll, Katharina, Puehler, T., Schunkert, H, Bissell, Malenka M. , Bolger, Aidan, Brion, M, Citro, Rodolfo, Deeb, G. Michael, Corte, Alessandro Della, Dina, C., Eriksson, Per, Evangelista, Arturo , Franco-Cereceda, Anders, Gilon, Dan, Hetherington, Simon, Huggins, G S, Krane, Markus , Tourneau, Thierry Le, Limongelli, Giuseppe, Mathieu, P., Messika-Zeitoun, David, Michelena, Hector I., Milewicz, Dianna, Murdock, David R. , Nickenig, G., Nistri, Stefano, Nöthen, M, Samani, Nilesh J. , Schott, J., Webb, Tom R., Abdelilah-Seyfried, Salim, Schumacher, Johannes, Trenkwalder, Teresa , Body, Simon C. , Dina, Christian , Brión, Marı́a , Peloso, Gina M. , Webb, Tom R. , Faucherre, Adèle , Debiec, Radoslaw M , Peloso, Gina M , Al-Kassou, Baravan , Aranki, Sary , Ashikhmina Swan, Elena , Björck, Hanna M , Boureau, Anne Sophie , Braund, Peter S , Folkersen, Lasse , Guo, Dongchuan , Heydarpour, Mahyar , Isselbacher, Eric M , Jopling, Chris , Laporte, Fabien , Le Scouarnec, Solena , Li, Zhonglin , Lichtner, Peter , Maj, Carlo , Manikpurage, Hasanga D , Nguyen, Thy B , Norris, Russell A , Pibarot, Phillippe , Sarubbi, Berardo , Simonet, Floriane , Sundt, Thoralf , Surakka, Ida , Tessler, Idit , Yang, Bo , Doppler, Stefanie A , Dreßen, Martina , Knoll, Katharina , Puehler, Thomas , Schunkert, Heribert , Bissell, Malenka M , Bossé, Yohan , Bossone, Eduardo , Brion, María , Citro, Rodolfo , de Vincentiis, Carlo , Deeb, G Michael , Della Corte, Alessandro , Dina, Christian , Durst, Ronen , Ensminger, Stephan , Eriksson, Per , Evangelista, Arturo , Franco-Cereceda, Anders , Gilon, Dan , Giusti, Betti , Hetherington, Simon L , Huggins, Gordon S , Le Tourneau, Thierry , Limongelli, Giuseppe , Mathieu, Patrick , Messika-Zeitoun, David , Michelena, Hector I , Milewicz, Dianna M , Muehlschlegel, Jochen D , Murdock, David R , Nickenig, Georg , Nistri, Stefano , Nöthen, Markus M , Prakash, Siddharth K , Samani, Nilesh J , Jacques Schott, Jean , Webb, Tom R , Zaffran, Stéphane , Eagle, Kim , Body, Simon C , Holdcraft, Jacob A., Bellino, Michele , Dagenais, François, Forte, Amalia , Frigiola, Alessandro , Guo, Dongchuan , Isselbacher, Eric M. , Nelson, Christopher P. , Ong, Chin Siang , Roychowdhury, Tanmoy , Surakka, Ida , Willer, Cristen J , Aviérinos, Jean-François , Bolger, Aidan P. , Bossé, Yohan , Bossone, Eduardo , Citro, Rodolfo , Deeb, G. Michael , Corte, Alessandro Della , Gilon, Dan, Huggins, Gordon S. , Tourneau, Thierry Le , Mathieu, Patrick , Messika–Zeitoun, David , Nistri, Stefano , Nöthen, Markus M. , Pluchinotta, Francesca Romana , Prakash, Siddharth K. , Schott, Jean‐Jacques , Zaffran, Stéphane , Abdelilah‐Seyfried, Salim , Eagle, Kim A. , Schumacher, Johannes

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 14 | Pages: 1060-1076

10.1161/circulationaha.125.074752 | PMID 41645906 Get It

BACKGROUND: Bicuspid aortic valve (BAV) is a frequent congenital heart defect with a high heritability. Despite this, only a limited number of genes have been associated with the disease, and the molecular mechanisms remain unexplained in most cases. This study aimed to further understand the genetic architecture of BAV. METHODS: A genome-wide association study meta-analysis including 9631 cases among 65 677 participants was performed. Genes were prioritized using transcriptomic analyses based on RNA sequencing in relevant tissues, including human fetal and adult aortic valves. The impact of the knockdown or knockout of 4 candidate genes on cardiac development was verified in zebrafish. A polygenic risk score was developed, its association with BAV was evaluated in an independent cohort, and its association with a wide range of phenotypes (n=976) was evaluated in UK Biobank (n=355 618 individuals). RESULTS: Thirty-six genomic loci were identified, including 32 that were not described previously. Among the prioritized genes, KANK2 and ERBB4 were identified as potentially causal through transcriptomic analyses, colocalization, and Mendelian randomization based on gene expression in human aortic valves (n=484), whereas PRDM6 and STRN were prioritized using similar analyses from aortic (n=326) and left ventricular tissues (n=326), respectively. Targeting 4 candidate genes ( WNT4 , LEF1 , STRN , and KANK2 ) in zebrafish led to disruption in cardiac development. A polygenic risk score was associated with an odds ratio of 2.07 (95% CI, 1.90–2.25; P =5.43×10 -62 ) per SD for BAV and significantly associated with thoracic aortic aneurysm and atrial fibrillation in UK Biobank. CONCLUSIONS: This study supports a significant polygenic contribution to BAV, where the combination of multiple common variants in genes involved in heart morphogenesis disrupts aortic valve development.
Radiological Insights into Alcohol Use Associated Disorders and Diseases: Part I
Nduwimana, Marie-Joy, Maheshwari, Sharad, Pratap, Thara , Helavar, Rajesh V, Patil, Aruna R., Rawat, Sudarshan, Khandelwal, Ashish , Menias, Christine O. , Venkatesh, Sudhakar K. , Venkatesh, Sudhakar K , Simon, Betty

Mayo Clinic

Indian Journal of Radiology and Imaging | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0045-1813745 Get It

Alcohol use disorder (AUD) is a significant public health challenge, affecting multiple organs and organ systems, and fetal health. Additionally, AUD also significantly contributes to self-harm and road accidents. Beyond its health effects, AUD creates economic and political challenges, including escalating treatment costs and the complex alcohol regulation policies. Despite global impact, AUD remains under-addressed in countries like India due to cultural norms and limited resources. Early recognition of AUD is vital for better outcomes, relying on thorough clinical evaluation and patient history. However, denial, inebriation, or lack of awareness often delays diagnosis. Imaging techniques like ultrasound, CT, and MRI effectively depict AUD-related organ damage and aid in detecting chronic alcohol use. Radiologists play a crucial role in identifying these manifestations, contributing to its early detection and treatment. This review article highlights the imaging of alcohol use related disorders and diseases affecting different organs and organ systems at various stages. The review is presented in two parts: the first focuses on alcohol burden, alcohol metabolism and toxicity, and imaging findings of AUD-related abdominal diseases and disorders.
Optimizing tuberculosis post-exposure follow-up among healthcare personnel using a risk-based approach
Samreen, Ayesha, Swift, Melanie D. , Breeher, Laura E. , Apenhorst, Debra, Rasmusson, Jenna, Loeffler, April, Anderson, J. Simon, Shah, Aditya , Samreen, Ayesha , Samreen, Ayesha , Apenhorst, Debra K, Rasmusson, Jenna M., Loeffler, April R, Anderson, Jennifer A, Shah, Aditya S , Swift, Melanie D , Breeher, Laura , Anderson, Jennifer A.

Mayo Clinic

Infection Control & Hospital Epidemiology | February 2, 2026 | Volume: 47 | Issue: 5 | Pages: 530-532

10.1017/ice.2026.10403 | PMID 41623146 Get It

Abstract Healthcare personnel (HCP) are at risk for occupational exposure to tuberculosis. Current guidelines for managing exposed HCP are broad and resource intensive. Based on review of our internal data, we propose a risk-based stratification approach to streamline exposure follow-up testing and optimize resource utilization.
Steroidal vs. non-steroidal mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction: a propensity-matched multi-network nationwide cohort study
Almas, Talal , Shelig, Mohamed , Al-Hindawi, Ahmed, Akbar, Absam , Qureshi, Amal Naveed, Ismayl, Mahmoud, Reed, Joseph, Burahmah, Jasem, AlHamlan, Abdullah W, AlMojil, Khaled, Almukhaizeem, Abdullah, Rana, Mariam , Alansari, Ali, Ramani, Ravi , Sullivan, Claire, Simon, Daniel I. , O'Neill, Thomas Joseph, Reed, Joseph A, Simon, Daniel I , Al-Hindawi, Ahmed , Bansal, Kannu , Ismayl, Mahmoud , Alhamlan, Abdullah W., Alansari, Ali, Zacharias, Michael P, Desai, Nihar R.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | January 29, 2026 | Volume: 12 | Issue: 5 | Pages: 718-730

10.1093/ehjqcco/qcag014 | PMID 41616082 Get It

Abstract Aims Heart failure (HF) continues to portend significant morbidity and mortality within the USA. Data regarding the efficacy of mineralocorticoid receptor antagonists (MRAs) in HF with preserved ejection fraction (HFpEF) remains unclear. Finerenone, a non-steroidal MRA, has demonstrated reduction in hospitalizations in this population. However, the comparative efficacy of different MRA classes in these patients remains elusive. Methods and results We conducted a retrospective observational cohort study using the TriNetX research network. We applied 1:1 propensity score matching (PSM) to compare patients with HFpEF initiated on finerenone vs. spironolactone. We examined 1-year risks of HF exacerbation, acute kidney injury (AKI), electrolyte derangements, and cardiovascular outcomes. We identified 254,417 patients with HFpEF and MRA use. After PSM, each cohort contained 491 patients. Analysis revealed that finerenone use was associated with a significantly lower risk of HF exacerbation (hazard ratio [HR] = 0.63 [95% confidence interval [CI]: 0.54, 0.74], P < 0.001), all-cause mortality (HR = 0.38 [95% CI: 0.23, 0.64], P < 0.001), and hypokalaemia (HR = 0.58 [95% CI: 0.40, 0.85], P = 0.001). The aforementioned results, along with a reduction in AKI risk, were statistically significant after stratified subgroup analysis by diabetes mellitus and chronic kidney disease. Conclusion In this large real-world HFpEF cohort, finerenone use was associated with lower risks of HF exacerbation and all-cause mortality compared with spironolactone. These observational findings are hypothesis-generating and warrant confirmation in randomized trials.
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Dutt, Shubir , Leichter, Dana, Wolf, Amy , Kornak, John , Clark, Annie L , Russell, Lucy L. , Bouzigues, Arabella , Cash, David M, Bocchetta, Martina , Olzinski, Molly, Ece, Bayram, Borroni, Barbara, Butler, Chris R., Clark, David, Convery, Rhian S., Darby, R. Ryan , Mendonça, Alexandre de, Dickerson, Bradford, Domoto‐Reilly, Kimiko, Ducharme, Simon, Ferry‐Bolder, Eve, Finger, Elizabeth, Foster, Phoebe H. , Galasko, Douglas R., Galimberti, Daniela, Gerhard, Alexander, Ghoshal, Nupur , Graff, Caroline, Graff‐Radford, Neill, Grant, Ian M., Hales, Chadwick M., Honig, Lawrence S., Hsiung, Ging‐Yuek, Huey, Edward D, Irwin, David John, Jiskoot, Lize C., Kremers, Walter K. , Kwan, Justin Y., Laforce, Robert, Ber, Isabelle Le, Levin, J, Litvan, Irene, Mackenzie, Ian R., Masellis, Mario, Mendez, Mario F., Moreno, Fermin, Onyike, Chiadi U. , Otto, M, Pascual, Belen, Pressman, Peter , Rademakers, Rosa, Ramos, Eliana Marisa , Ritter, Aaron, Roberson, Erik D. , Sánchez‐Valle, Raquel, Santana, Isabel, Seelaar, Harro, Snyder, Allison, Sorbi, Sandro, Synofzik, Matthis, Tartaglia, Maria Carmela, Swieten, John C. van, Vandebergh, Marijne , Vandenberghe, Rik, Heuer, Hilary W. , Miller, Bruce L., Seeley, William W., Gorno‐Tempini, Maria Luisa, Kramer, Joel H., Forsberg, Leah K., Kantarci, Kejal, Boeve, Bradley F., Boxer, Adam L. , Rohrer, J. D., Rosen, Howard J., Staffaroni, Adam M., investigators, FTD Prevention Initiative (FPI), Graff, Caroline , Galimberti, Daniela , Otto, Markus , Jiskoot, Lize C. , Moreno, Fermín , Domoto‐Reilly, Kimiko , Russell, Lucy L , Bocchetta, Martina , Bayram, Ece , Ducharme, Simon , Finger, Elizabeth C. , Galimberti, Daniela , Ghoshal, Nupur , Irwin, David J , Kwan, Justin Y , Le Ber, Isabelle , Otto, Markus , Pascual, Belen , Snyder, Allison , Synofzik, Matthis , Tartaglia, Maria Carmela , Tiraboschi, Pietro , Kantarci, Kejal , Rohrer, Jonathan D , Roberson, Erik , Kremers, Walter K , Domoto-Reilly, Kimiko , Vandebergh, Marijne , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Cobigo, Yann , Cash, David M. , Appleby, Brian S. , Borroni, Barbara , Bozoki, Andrea C , Clark, David, Convery, Rhian , Mendonça, Alexandre de , Ducharme, Simon , Ferry‐Bolder, Eve , Galasko, Douglas , Gerhard, Alexander , Graff‐Radford, Neill R. , Hales, Chadwick M. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kwan, Justin , Laforce, Robert , Ber, Isabelle Le , Léger, Gabriel C. , Xiong, Chengjie , Litvan, Irene , Mackenzie, Ian R. , Masellis, Mario , Mendez, Mario F. , Pascual, Belén , Rademakers, Rosa , Rowe, James B. , Sánchez‐Valle, Raquel , Santana, Isabel , Seelaar, Harro , Snyder, Allison , Sorbi, Sandro , Synofzik, Matthis , Tiraboschi, Pietro , Swieten, John C. van , Vandenberghe, Rik , Seeley, William W. , Gorno‐Tempini, Maria‐Luisa, Kramer, Joel H. , Forsberg, Leah K. , Kantarci, Kejal , Boeve, Bradley F. , Rohrer, Jonathan D. , Rosen, Howard J. , Staffaroni, Adam M.

Mayo Clinic

Annals of Neurology | January 29, 2026 | Volume: 99 | Issue: 5 | Pages: 1315-1326

10.1002/ana.78167 | PMID 41608854 Get It

Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a